Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis

Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):335-337. doi: 10.1093/ehjcvp/pvaa074.

Affiliations

¹ Division of Cardiology, C.A.S.T., Azienda Ospedaliero-Universitaria 'Policlinico-San Marco', University of Catania, Catania, Italy.
² Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

No abstract available

Publication types

Letter
Meta-Analysis
Systematic Review

MeSH terms

Angiotensin Receptor Antagonists / adverse effects
Angiotensin Receptor Antagonists / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / adverse effects
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Antiviral Agents / adverse effects
Antiviral Agents / therapeutic use*
Betacoronavirus / drug effects*
Betacoronavirus / pathogenicity
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy*
Coronavirus Infections / metabolism
Coronavirus Infections / mortality
Coronavirus Infections / virology
Host-Pathogen Interactions
Humans
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / metabolism
Pneumonia, Viral / mortality
Pneumonia, Viral / virology
Renin-Angiotensin System / drug effects*
Risk Factors
SARS-CoV-2
Treatment Outcome

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Antiviral Agents